EFFECTS OF THE BET-INHIBITOR APABETALONE ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ACUTE CORONARY SYNDROME, ACCORDING TO PRESENCE OR ABSENCE OF CHRONIC KIDNEY DISEASE. A BETONMACE TRIAL REPORT

被引：0

作者：

Kalantar-Zadeh, Kam ^{[1
]}

Ray, Kausik K. ^{[2
]}

Nicholls, Stephen J. ^{[3
]}

Ginsburg, Henry N. ^{[4
]}

Buhr, Kevin A. ^{[5
]}

Johansson, Jan ^{[6
]}

Kulikowski, Ewelina ^{[7
]}

Toth, Peter P. ^{[8
]}

Sweeney, Michael ^{[6
]}

Schwartz, Gregory G. ^{[9
]}

机构：

[1] Univ Calif Irvine, Div Nephrol & Hypertens, Irvine, CA USA

[2] Imperial Coll, Imperial Ctr Cardiovasc Dis Prevent, London, England

[3] Monash Univ, MonashHeart, Melbourne, Vic, Australia

[4] Columbia Univ, New York, NY USA

[5] Univ Wisconsin, Stat Data Anal Ctr, Madison, WI USA

[6] Resverlogix Corp, San Francisco, CA USA

[7] Resverlogix Corp, Res, Calgary, AB, Canada

[8] Univ Illinois, Coll Med, Dept Family & Community Med, Peoria, IL 61656 USA

[9] VA Denver Aurora, Div Cardiol, Aurora, CO USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

TO001

引用

页码：182 / 182

页数：1

共 50 条

[1] APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE, TYPE 2 DIABETES, AND RECENT ACUTE CORONARY SYNDROME: A BETONMACE TRIAL REPORT
Kalantar-Zadeh, Kamyar
Nicholls, Stephen J.
Buhr, Kevin A.
Ginsburg, Henry N.
Johansson, Jan
Kulikowski, Ewelina
Toth, Peter P.
Wong, Norman
Sweeney, Michael
Schwartz, Gregory G.
Ray, Kausik K.
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (05) : 819 - 819
[2] Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial
Schwartz, Gregory G.
Nicholls, Stephen J.
Ginsberg, Henry
Johansson, Jan
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Toth, Peter P.
Wong, Norman
Sweeney, Michael
Ray, Kausik K.
[J]. CIRCULATION, 2020, 142
[3] THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL
Toth, Peter P.
Schwartz, Gregory G.
Nicholls, Stephen J.
Johansson, Jan
Ginsberg, Henry
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Wong, Norman C.
Szarek, Michael
Sweeney, Michael
Ray, Kausik Kumar
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1104 - 1104
[4] Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
Ray, Kausik K.
Nicholls, Stephen J.
Ginsberg, Henry N.
Johansson, Jan O.
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Toth, Peter P.
Wong, Norman
Sweeney, Michael
Schwartz, Gregory G.
[J]. CIRCULATION, 2019, 140 (25) : E966 - E966
[5] Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Ray, Kausik K.
Nicholls, Stephen J.
Ginsberg, Henry D.
Johansson, Jan O.
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Toth, Peter P.
Wong, Norman
Cummings, Jeffrey L.
Sweeney, Michael
Schwartz, Gregory G.
[J]. AMERICAN HEART JOURNAL, 2019, 217 : 72 - 83
[6] THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL
Sweeney, Michael
Nicholls, Stephen J.
Ray, Kausik Kumar
Buhr, Kevin
Ginsberg, Henry
Johansson, Jan
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Toth, Peter
Wong, Norman
Schwartz, Gregory G.
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 168 - 168
[7] Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes
Ray, K. K.
Nicholls, S. J.
Buhr, K. A.
Ginsberg, H. N.
Kalantar-Zadeh, K.
Johansson, J. O.
Kulikowski, E.
Toth, P. P.
Wong, N.
Sweeney, M.
Schwartz, G. G.
[J]. EUROPEAN HEART JOURNAL, 2020, 41 : 1425 - 1425
[8] DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES
Kalantar-Zadeh, Kam
Johansson, Jan
Kulikowski, Ewelina
Halliday, Christopher
Lebioda, Ken
Sweeney, Mike
Wong, Norman
Nicholls, Stephen
Schwartz, Gregory
Ray, Kausik
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
[9] Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus
Lessey, Gayatri
Stavropoulos, Konstantinos
Papademetriou, Vasilios
[J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2019, 15 : 365 - 373
[10] Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
Toth, Peter P.
Schwartz, Gregory G.
Nicholls, Stephen J.
Khan, Aziz
Szarek, Michael
Ginsberg, Henry N.
Johansson, Jan O.
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Lebioda, Ken
Wong, Norman C. W.
Sweeney, Michael
Ray, Kausik K.
[J]. AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 11

← 1 2 3 4 5 →